Crescent Biopharma will present at investor conferences in June, showcasing its oncology therapies and clinical pipeline.
Quiver AI Summary
Crescent Biopharma, Inc., a clinical-stage biotechnology company focused on developing cancer therapies, announced its participation in two upcoming investor conferences in June 2026. The management will present at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, with live webcasts of both events available on their website. Crescent is dedicated to advancing its clinical pipeline, which includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, aiming to develop transformative therapies for solid tumors. For further details, one can visit their website or follow them on social media platforms.
Potential Positives
- Crescent Biopharma is actively engaging with the investment community by presenting at notable healthcare conferences, which can enhance its visibility and attract potential investors.
- The company showcases a diverse clinical-stage pipeline intended for the treatment of cancer, indicating a commitment to innovation and potential market growth.
- The availability of live webcasts and replays for presentations suggests transparency and a willingness to keep investors informed, fostering trust and interest.
Potential Negatives
- The press release does not provide any updates on the progress of its clinical-stage pipeline, leaving investors without any new information on the company's development efforts or timelines.
- The lack of specific details regarding the anticipated outcomes or goals for the presentations at investor conferences may raise concerns about the company's preparedness or the status of its projects.
- Overall, the press release focuses primarily on event announcements rather than significant achievements or breakthroughs, potentially indicating a lack of recent progress or milestones in the company’s operations.
FAQ
What investor conferences will Crescent Biopharma participate in?
Crescent Biopharma will present at the Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June 2026.
When is Crescent Biopharma's presentation at the Jefferies conference?
The presentation at the Jefferies Global Healthcare Conference is scheduled for June 3, 2026, at 4:20 p.m. ET.
How can I watch Crescent Biopharma's presentations live?
A live webcast of each presentation will be available on Crescent Biopharma's Investors section of their website.
What innovative therapies is Crescent Biopharma developing?
Crescent Biopharma is developing a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs) for cancer treatment.
Who can I contact for more information about Crescent Biopharma?
For investor inquiries, contact Amy Reilly, and for media inquiries, contact Jenna Poist at Crescent Biopharma.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CBIO Insider Trading Activity
$CBIO insiders have traded $CBIO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CBIO stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT purchased 1,360,000 shares for an estimated $18,237,600
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CBIO Hedge Fund Activity
We have seen 34 institutional investors add shares of $CBIO stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. added 1,398,318 shares (+1251.7%) to their portfolio in Q1 2026, for an estimated $25,687,101
- VR ADVISER, LLC added 745,712 shares (+53.7%) to their portfolio in Q4 2025, for an estimated $8,844,144
- ADAR1 CAPITAL MANAGEMENT, LLC removed 555,727 shares (-91.7%) from their portfolio in Q1 2026, for an estimated $10,208,704
- BOXER CAPITAL MANAGEMENT, LLC removed 453,686 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $8,334,211
- COMMODORE CAPITAL LP removed 450,829 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,346,831
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 302,457 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $5,556,135
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 272,951 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,237,198
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$CBIO Analyst Ratings
Wall Street analysts have issued reports on $CBIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 01/21/2026
To track analyst ratings and price targets for $CBIO, check out Quiver Quantitative's $CBIO forecast page.
$CBIO Price Targets
Multiple analysts have issued price targets for $CBIO recently. We have seen 2 analysts offer price targets for $CBIO in the last 6 months, with a median target of $28.5.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $22.0 on 03/02/2026
- Brad Canino from Guggenheim set a target price of $35.0 on 01/21/2026
Full Release
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:
- 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 4:20 p.m. ET in New York
- Goldman Sachs 47 th Annual Global Healthcare Conference, fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations , and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X .
Contacts
Investors
Amy Reilly
Chief Communications Officer
[email protected]
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
[email protected]
781-671-5019
